Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

Myelodysplastic Syndromes Clinical Trial

Official title:

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04539236
• Other study ID #: 20201503
• Secondary ID: CASE2920
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: November 9, 2021
• Est. completion date: August 1, 2029

Study information

• Verified date: September 2023
• Source: University of Miami
• Contact: Mikkael Sekeres, MD
• Phone: 305-243-9974
• Email: mxs3108[@]miami.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate if the combination of drugs, Lenalidomide and Luspatercept, will help improve the treatment of anemia in patients with lower-risk Myelodysplastic Syndrome (MDS).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: August 1, 2029
• Est. primary completion date: August 1, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject is = 18 years of age the time of signing the informed consent form (ICF).

2. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.

3. Documented diagnosis of MDS according to World Health Organization (WHO) / French-American-British (FAB) classification that meets International Prognostic Scoring System Revised (IPSS-R) classification (Greenberg, 2012) of very low, low, or intermediate risk disease; intermediate patients must have a blast percentage <5% to be enrolled.

4. Refractory or intolerant to, or ineligible for, prior Erythropoiesis-stimulating agents (ESA) treatment, as defined by any one of the following:

• Refractory to prior ESA treatment - documentation of non-response or response that is no longer maintained to prior ESA-containing regimen, either as single agent or combination (eg, with G-CSF); ESA regimen must have been either:

• recombinant human erythropoietin (rHu EPO) = 40,000 IU/week for at least 8 doses or equivalent; OR

• darbepoetin alpha = 200-500 µg Q1-3W for at least 4 doses or equivalent;

• Intolerant to prior ESA treatment - documentation of discontinuation of prior ESA-containing regimen, either as single agent or combination (eg, with G-CSF), at any time after introduction due to intolerance or an adverse event

• ESA ineligible - Low chance of response to ESA based on endogenous serum erythropoietin level > 200 U/L for subjects not previously treated with ESAs

5. If previously treated with ESAs, agents must have been discontinued = 4 weeks prior to date of C1D1.

6. Requires RBC transfusions, as documented by the following criteria:

• average transfusion requirement of = 2 units/8 weeks of packed Red Blood Cells (pRBC) s confirmed for a minimum of 16 weeks immediately preceding C1D1.

• Hemoglobin levels at the time of or within 7 days prior to administration of a RBC transfusion must have been = 10.0 g/dL for the transfusion to be counted towards meeting eligibility criteria. Red blood cell transfusions administered when Hgb levels were > 10.0 g/dL and/or RBC transfusions administered for elective surgery will not qualify as a required transfusion for the purpose of meeting eligibility criteria.

• no consecutive 56-day period that was RBC transfusion-free during the 16 weeks immediately preceding C1D1.

7. Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 (Appendix 1)

8. Females of childbearing potential (FCBP), defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months), must:

• Have two negative pregnancy tests (urine or serum) as verified by the Investigator prior to starting study therapy (unless the screening pregnancy test was done within 72 hours of C1D1). She must agree to ongoing pregnancy testing during the course of the study, and after end of study treatment.

• If sexually active, agree to use, and be able to comply with, highly effective contraception without interruption, 5 weeks prior to starting investigational product, during the study therapy (including dose interruptions), and for 12 weeks after discontinuation of study therapy.

9. Male subjects must:

• Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (for example, polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 12 weeks following investigational product discontinuation, even if he has undergone a successful vasectomy.

10. Subject must have a negative Coronavirus Disease of 2019 (COVID-19) test completed =7 days prior to administration of protocol therapy.

11. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. Prior therapy with Lenalidomide.

2. Previously treated with either luspatercept (ACE-536) or sotatercept (ACE-011)

3. MDS associated with del 5q cytogenetic abnormality

4. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding

• iron deficiency to be determined by serum ferritin = 15 µg/L and additional testing if clinically indicated (eg, calculated transferrin saturation [iron/total iron binding capacity = 20%] or bone marrow aspirate stain for iron).

5. Prior allogeneic stem cell transplant

6. Known history of diagnosis of AML

7. Use of any of the following within 4 weeks prior to C1D1:

• anticancer cytotoxic chemotherapeutic agent or treatment

• other RBC hematopoietic growth factors (eg, Interleukin-3)

• investigational drug or device, or approved therapy for investigational use. If the half-life of the previous investigational product is known, use within 5 times the half-life prior to C1D1 or within 5 weeks, whichever is longer is excluded.

8. Uncontrolled hypertension, defined as repeated elevations of diastolic blood pressure (DBP) = 100 mmHg despite adequate treatment.

9. Prior history of malignancies, other than MDS, unless the subject has been free of the disease (including completion of any active or adjuvant treatment for prior malignancy) for = 1 year. However, subjects with the following history/concurrent conditions involving in situ cancer (or similar) are allowed:

• Basal or squamous cell carcinoma of the skin

• Carcinoma in situ of the cervix

• Carcinoma in situ of the breast

• Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis (TNM) clinical staging system)

10. Major surgery within 4 weeks prior to C1D1. Subjects must have completely recovered from any previous surgery prior to C1D1

11. History of stroke, deep venous thrombosis (DVT), pulmonary or arterial embolism within 6 months prior to C1D1

12. Pregnant or breastfeeding females

13. Subject has any significant medical condition, laboratory abnormality, psychiatric illness, or is considered vulnerable by local regulations (eg, imprisoned or institutionalized) that, in the opinion of the Investigator, would prevent the subject from participating in the study.

Related Conditions & MeSH terms

• Myelodysplastic Syndromes

Intervention

Drug:
• Lenalidomide
Administered daily by mouth on a 21 day cycle. Doses will be administered at 2.5 mg, 5 mg and 10 mg.
• Luspatercept
Administered subcutaneously in the upper arm, thigh and/or abdomen on Day 1 of a 21 day cycle. Starting dose will be at 1.0 mg/kg and can be titrated, dependent on participant response, to doses of 1.33 mg/kg, and 1.75 mg/kg.

Locations

Country	Name	City	State
United States	Johns Hopkins University	Baltimore	Maryland
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Cleveland Clinic	Cleveland	Ohio
United States	University of Miami	Miami	Florida
United States	Cornell University	New York	New York
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (3)

Lead Sponsor	Collaborator
Mikkael Sekeres, MD	Bristol-Myers Squibb, Celgene

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	MTD/RP2D of Luspatercept combined with Lenalidomide	Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of Luspatercept combined with Lenalidomide (reported in mg/kg) from Phase Ib portion of study	Up to 15 weeks
Primary	DLT Rate for Phase Ib	DLT rate is defined as the percentage of participants with Dose Limiting Toxicities (DLT) as evaluated by treating physician using the National Cancer Center (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. DLTs are non-hematologic events grade 3 or higher that are at least possibly related to the investigational product and do not resolve to grade 1 or lower within 21 days.	Up to 15 weeks
Primary	Percentage of participants with RBC-TI response	Red Blood Cell Transfusion Independence (RBC-TI) response is defined as participants who are RBC transfusion free over any consecutive 56-day period	Up to 5 years
Primary	Toxicity Rate for Phase II	Toxicity rate is defined as the percentage of participants with treatment emergent adverse events (TE-AEs) as evaluated by treating physician using the National Cancer Center (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Up to 5 years
Secondary	Percentage of participants with relevant reduction in RBC transfusion requirement	Participants with relevant reduction in RBC transfusion requirement will be defined as those participants whose total number of RBC units transfused has decreased by at least 4 units compared to the number transfused during the 8 weeks before study participation	Up to 5 years
Secondary	Percentage of participants with Erythroid Response	Hematologic Improvement Erythroid Response (HI-E) will bdefined as at least a 1.5 g/dl increase in serum hemoglobin from baseline	Up to 5 years
Secondary	Duration of RBC-TI	The length of time where participants are RBC transfusion free will be reported	Up to 5 years
Secondary	Percentage of participants with Platelet Response	Hematologic improvement Platelet response (HI-P) will be defined as: For participants with a serum baseline platelet count of > 20,000/mm3 at baseline: An absolute increase of = 30,000/mm3 from baseline; For participants with a serum platelet count = 20,000/mm3 at baseline: An increase of at least 100% from baseline counts to a platelet count > 20,000/mm3.	Up to 5 years
Secondary	Percentage of participants with Neutrophil Response	Hematologic improvement of Neutrophil Response (HI-N) will be defined as a serum absolute neutrophil count (ANC) increase from baseline of at least 100%, and an absolute increase of > 500/mm3 from baseline.	Up to 5 years
Secondary	Percentage of participants experiencing a progression to higher-risk MDS or AML	Percentage of participants experiencing a progression to higher-risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)	Up to 5 years
Secondary	Overall Survival (OS)	OS is calculated for all participants from the date of initial registration to date of death due to any cause. The follow-up for participants last known to be alive is censored at the date of last contact.	Up to 5 years
Secondary	Percentage of participants with RBC-TI lasting 16 weeks	Percentage of participants with RBC-TI lasting 16 weeks (112 days) will be assessed per the Blood 2019 position paper on defining response in lower-risk MDS	Up to 5 years